I agree that this site is using cookies. You can find further informations here.
X
Armuzzi, A
1036  results:
Search for persons X
?
1

Golimumab improves health-related quality of life of patien..:

Saibeni, S. ; Bezzio, C. ; Bossa, F....
Digestive and Liver Disease.  56 (2024)  1 - p. 83-91 , 2024
Link: https://doi.org/10.1016/..
 
?
2

P715 Multiparametric assessment of IBD and SpA-IBD patients..:

Privitera, G ; Parisio, L ; Perniola, S...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1346-i1346 , 2024
Link: https://doi.org/10.1093/..
 
?
3

BOC.03.1: EFFECTIVENESS AND SAFETY OUTCOMES BEYOND FIVE YEA..:

Privitera, G. ; Pugliese, D. ; Armuzzi, A.
Digestive and Liver Disease.  56 (2024)  - p. S114 , 2024
Link: https://doi.org/10.1016/..
 
?
4

T.05.5: EFFECTIVENESS OF UPADACITINIB IN PATIENTS WITH ULCE..:

Teani, I. ; Bevilacqua, N. ; Gabbiadini, R....
Digestive and Liver Disease.  56 (2024)  - p. S244-S245 , 2024
Link: https://doi.org/10.1016/..
 
?
5

OC.09.2: ENDOSCOPIC SUBMUCOSAL DISSECTION FOR HIGH-RISK COL..:

Maselli, R. ; De Sire, R. ; Barbaro, F....
Digestive and Liver Disease.  56 (2024)  - p. S177 , 2024
Link: https://doi.org/10.1016/..
 
?
6

P789 Impact of risk factors for Janus kinase inhibitor use ..:

Siegmund, B ; Kuehbacher, T ; Armuzzi, A...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1471-i1473 , 2024
Link: https://doi.org/10.1093/..
 
?
7

P881 Real-life vs trial access to biologic therapy differen..:

DI VINCENZO, F ; Maresca, R ; Mora, V...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1624-i1624 , 2024
Link: https://doi.org/10.1093/..
 
?
8

P535 Effectiveness of upadacitinib in patients with Ulcerat..:

Teani, I ; Bevilacqua, N ; Gabbiadini, R...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1052-i1053 , 2024
Link: https://doi.org/10.1093/..
 
?
9

P456 Pragmatic trial design to compare real-world effective..:

Fantini, M C ; Fiorino, G ; Colli, A...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i922-i923 , 2024
Link: https://doi.org/10.1093/..
 
?
10

OC.07.7: SUSTAINED IMPROVEMENT IN INFLAMMATORY BOWEL DISEAS..:

Sands, B.E. ; Feagan, B.G. ; Armuzzi, A....
Digestive and Liver Disease.  56 (2024)  - p. S166 , 2024
Link: https://doi.org/10.1016/..
 
?
11

OP06 Risankizumab Maintenance Therapy in Patients With Mode..:

Louis, E ; Panaccione, R ; Parkes, G...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i10-i12 , 2024
Link: https://doi.org/10.1093/..
 
?
12

OP36 Risankizumab Versus Ustekinumab for the Achievement of..:

Dubinsky, M C ; D'Haens, G ; Atreya, R...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i65-i66 , 2024
Link: https://doi.org/10.1093/..
 
?
13

P1065 Endoscopic Submucosal Dissection for High-Risk Colore..:

Maselli, R ; de Sire, R ; Barbaro, F...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1914-i1914 , 2024
Link: https://doi.org/10.1093/..
 
?
14

P508 Pre-operative exposure to tofacitinib is as safe as bi..:

Dragoni, G ; Innocenti, T ; Amiot, A...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1005-i1006 , 2024
Link: https://doi.org/10.1093/..
 
?
15

P055 GPR43 and GPR84 play a crucial role in supporting peri..:

Rubbino, F ; Di Cristofaro, A ; Wozny, M...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i322-i322 , 2024
Link: https://doi.org/10.1093/..
 
1-15